DEC 18, 2016 7:06 AM PST

Leukemia Stunted into Remission via Fasting

WRITTEN BY: Xuan Pham

The newest leukemia research findings suggest that intermittent fasting may literally starve the cancer cells too. The study, by the University of Texas Southwestern Medical Center, explores different pathways by which acute lymphoblastic leukemia may be targeted more successfully.

Image credit: Pixabay.com

Though considered a rare disease, acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer, peaking in early childhood between the ages of 2 and 4. The cancer involves the overproduction of immature white blood cells in the bone marrow. These cancerous cells invade the blood and other organ systems, causing massive cell death and damage in a short amount of time.

Fortunately, doctors have an arsenal of weapons that are effective against ALL. These include radiation therapy, bone marrow transplantation, and chemotherapy agents like methotrexate, vincristine, and cytarabine. With treatment, the 5-year survival rate for the majority of ALL patients is 70 percent. However, remission isn’t a sustained outcome in 15 to 20 percent of children in whom the cancer makes a dreaded comeback.

Based on previous research that suggests fasting may augment chemotherapy outcome, researchers at UT Southwestern decided to investigate this line of treatment in several mouse models of ALL. The mice received either normal feeding or were subject to a dietary restriction consistent with intermittent fasting.

"Strikingly, we found that in models of ALL, a regimen consisting of six cycles of 1 day of fasting followed by 1 day of feeding completely inhibited cancer development," reported Chengcheng Zhang, associate professor at UT Southwestern, and the study’s lead author.

Within 7 weeks on the fasting diet, the mice had undetectable levels of leukemia cells in the bone marrow and spleen, a promising sign of disease remission. By contrast, mice on the normal diet regimen contained nearly 70 percent of cancerous cells in the affected organs.

"Although initially cancerous, the few fluorescent cells that remained in the fasted mice after 7 weeks appeared to behave like normal cells. Mice in the ALL model group that ate normally died within 59 days, while 75 percent of the fasted mice survived more than 120 days without signs of leukemia,” reported Zhang.

The exact mechanism behind this effect is yet to be fully understood. However, Zhang’s team suspect it involves leptin, a “satiety hormone” released to inhibit the hunger sensation. "We found that fasting decreased the levels of leptin circulating in the bloodstream as well as decreased the leptin levels in the bone marrow," said Zhang. "These effects became more pronounced with repeated cycles of fasting," he adds. "After fasting, the rate at which the leptin levels recovered seemed to correspond to the rate at which the cancerous ALL cells were cleared from the blood."

While the results have big implications for leukemia research and treatment, fasting as a treatment for ALL has still yet to be tested in human clinical trials. And until such trial delivers the same promising results, patients or caretakers should not yet consider fasting as a treatment plan.

Additional sources: MNT 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 07, 2021
Cancer
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
JUL 07, 2021
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
Researchers from Australia have found that the conventional chemotherapy used to treat various cancers disrupts the comp ...
JUL 26, 2021
Genetics & Genomics
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
JUL 26, 2021
A Region of Non-Coding DNA That May Help Regulate Telomere Length is ID'ed
Many types of cells have to be replenished continuously throughout our lives, and the genome in the nucleus of those cel ...
OCT 07, 2021
Cancer
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
OCT 07, 2021
Dual Threat: CAR T Cells Modified to Target Two Neuroblastoma Antigens
Neuroblastoma is a cancer of immature nerve cells found in various areas, including the adrenal glands, neck, chest ...
OCT 14, 2021
Clinical & Molecular DX
Weighing Cancer Cells Helps Predict Treatment Outcomes
OCT 14, 2021
Weighing Cancer Cells Helps Predict Treatment Outcomes
Not all cancer patients respond to oncology treatments in the same way. Some might show signs of improvement as the ther ...
NOV 05, 2021
Cancer
The Labroots 2021 Cancer Research and Oncology Virtual Event Poster Winner
NOV 05, 2021
The Labroots 2021 Cancer Research and Oncology Virtual Event Poster Winner
Every year, Labroots hosts an exciting series of Virtual Events that focus on various scientific topics. These virtual m ...
NOV 09, 2021
Microbiology
Can This Cat Parasite Become a Tumor Treatment?
NOV 09, 2021
Can This Cat Parasite Become a Tumor Treatment?
You may have heard of Toxoplasma gondii because it is so common. Cats carry this parasite, and anyone that cleans a litt ...
Loading Comments...